On October 3, 2024, Jeffrey Dierks, the Chief Commercial Officer of Harmony Biosciences Holdings Inc (HRMY, Financial), executed a significant transaction by selling 36,357 shares of the company. The sale was documented in a recent SEC Filing. Following this transaction, the insider now owns 0 shares in the company.
Harmony Biosciences Holdings Inc (HRMY, Financial) is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases. The company's commitment to addressing unmet medical needs in this area has positioned it as a key player in the biopharmaceutical sector.
Over the past year, Jeffrey Dierks has sold a total of 84,576 shares and has not made any purchases of the company's stock. This recent sale is part of a broader trend observed within the company, where there have been 5 insider sells and no insider buys over the same timeframe.
Shares of Harmony Biosciences Holdings Inc were trading at $35.06 on the day of the transaction. The company currently holds a market cap of approximately $1.95 billion. The price-earnings ratio of the stock stands at 17.63, which is lower than both the industry median of 27.79 and the company’s historical median.
According to the GF Value, the intrinsic value of Harmony Biosciences Holdings Inc is estimated at $80.73 per share, suggesting that the stock is significantly undervalued with a price-to-GF-Value ratio of 0.43.
The GF Value is calculated based on historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company’s past returns and growth, and future business performance estimates from Morningstar analysts.
This sale by the insider may be of interest to current and potential investors, providing insight into the insider's perspective on the stock's valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
